Literature DB >> 30598237

Spinal muscular atrophy with respiratory distress type 1: A multicenter retrospective study.

Agnès Viguier1, Valérie Lauwers-Cances2, Pascal Cintas3, Véronique Manel4, Sylviane Peudenier5, Isabelle Desguerre6, Susana Quijano-Roy7, Catherine Vanhulle8, Mélanie Fradin9, Arnaud Isapof10, Michaël Jokic11, Michèle Mathieu-Dramard12, Klaus Dieterich13, Florence Petit14, Corinne Magdelaine15, Fabienne Giuliano16, Domitille Gras17, Damien Haye18, Mathilde Nizon19, Maryse Magen19, Eric Bieth20, Claude Cances21.   

Abstract

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a rare autosomal recessive neuromuscular disorder characterized by progressive motor and respiratory decline during the first year of life. Early and late-onset cases have recently been reported, although not meeting the established diagnostic criteria, these cases have been genotyped. We thus conducted a national multicenter observational retrospective study to determine the prognosis of children with SMARD1 according to their phenotype. We recorded all known French pediatric cases with mutations identified on the immunoglobulin μ-binding protein 2 gene and the presence of respiratory symptoms. Thirty centers provided 22 observations. A diaphragmatic palsy was diagnosed 1.5 months (p = 0.02) after first respiratory symptoms, and hypotonia preceded areflexia by 4 months (p = 0.02). Early onset of symptoms leading to specialist consultation before the age of 3 months was associated with a significantly worse prognosis (p < 0.01). Among the 6 patients who were still alive, all were tracheostomized. Only one case survived beyond 2 years without artificial ventilation. The remaining patients died at a median age of 7 months. Our results may help pediatricians to provide medical information to parents and improve the decision-making process of setting up life support.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DSMA1; Heterogeneity; IGHMBP2; Multicenter; Prognosis; SMARD1

Mesh:

Substances:

Year:  2018        PMID: 30598237     DOI: 10.1016/j.nmd.2018.10.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

1.  Severe Infantile Axonal Neuropathy with Respiratory Failure Caused by Novel Mutation in X-Linked LAS1L Gene.

Authors:  Agnieszka Stembalska; Małgorzata Rydzanicz; Wojciech Walas; Piotr Gasperowicz; Agnieszka Pollak; Victor Murcia Pienkowski; Mateusz Biela; Magdalena Klaniewska; Zuzanna Gamrot; Ewa Gronska; Rafal Ploski; Robert Smigiel
Journal:  Genes (Basel)       Date:  2022-04-21       Impact factor: 4.141

Review 2.  The future is here: Integrating genetics into the pediatric pulmonary clinic.

Authors:  Megan H Hawley; Peter P Moschovis; Mengdi Lu; T Bernard Kinane; Lael M Yonker
Journal:  Pediatr Pulmonol       Date:  2020-07

Review 3.  Spinal muscular atrophy with respiratory distress type 1: Clinical phenotypes, molecular pathogenesis and therapeutic insights.

Authors:  Matteo Saladini; Monica Nizzardo; Alessandra Govoni; Michela Taiana; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  J Cell Mol Med       Date:  2019-12-04       Impact factor: 5.310

4.  Clinical phenotype and loss of the slow skeletal muscle troponin T in three new patients with recessive TNNT1 nemaline myopathy.

Authors:  Justine Géraud; Klaus Dieterich; John Rendu; Mireille Cossee; Claude Cances; Emmanuelle Uro Coste; Murielle Dobrzynski; Pascale Marcorelle; Christine Ioos; Norma Beatriz Romero; Eloise Baudou; Julie Brocard; Anne-Cécile Coville; Julien Fauré; Michel Koenig; Raul Juntas Morales; Emmanuelle Lacène; Angéline Madelaine; Isabelle Marty; Henri Pegeot; Corinne Theze; Aurore Siegfried
Journal:  J Med Genet       Date:  2020-09-29       Impact factor: 6.318

5.  Validation of the Pathogenic Effect of IGHMBP2 Gene Mutations Based on Yeast S. cerevisiae Model.

Authors:  Weronika Rzepnikowska; Joanna Kaminska; Andrzej Kochański
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.